Quantcast

Latest Bayer HealthCare Pharmaceuticals Inc. Stories

2014-07-09 08:27:56

- Awareness campaign aims to break world record for largest display of origami boats to show widespread support for GIST community WHIPPANY, N.J. and WAYNE, N.J., July 9, 2014 /PRNewswire/ -- To raise awareness about gastrointestinal stromal tumors (GIST), the Life Raft Group, a leading GIST advocacy organization, designates Sunday, July 13, 2014 as worldwide GIST Awareness Day, through a presenting sponsorship from Bayer HealthCare. At the center of the awareness activities is a global...

2014-06-02 23:01:50

Individuals who allege similar pseudotumor injuries associated with use of the Mirena system have asked the U.S. Judicial Panel on Multidistrict Litigation for separate consolidation of their lawsuits. Port Washington, NY (PRWEB) June 02, 2014 Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs and medical devices, announces that individuals who have brought lawsuits against Bayer Healthcare Pharmaceuticals Inc. over its Mirena...

2014-06-02 08:31:45

The inserter features a thin, flexible insertion tube and enables single-handed loading WHIPPANY, N.J., June 2, 2014 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. today announced Food and Drug Administration (FDA) approval of a new inserter for Mirena(®). Bayer now offers the same inserter design and technique for both Mirena and Skyla(® )(levonorgestrel-releasing intrauterine system) 13.5 mg. (Photo: http://photos.prnewswire.com/prnh/20140531/92968) The innovative Bayer Inserter...

2014-05-14 16:29:06

WHIPPANY, N.J., May 14, 2014 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. announced today that data from its oncology portfolio, including NEXAVAR(®) (sorafenib) tablets, Xofigo(®) (radium Ra 223 dichloride) injection and Stivarga(®) (regorafenib) tablets, will be presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), May 30 - June 3, in Chicago, IL (USA). Bayer will also present data from its late stage clinical pipeline, investigating...

2014-05-12 08:31:01

- Kogenate® FS antihemophilic factor (recombinant) approved for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults with hemophilia A WHIPPANY, N.J., May 12, 2014 /PRNewswire/ -- Bayer HealthCare announced today that the U.S. Food and Drug Administration (FDA) has approved a new indication for Bayer's Kogenate® FS antihemophilic factor VIII (recombinant), for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults...

2014-05-09 08:26:43

WHIPPANY, N.J., May 9, 2014 /PRNewswire/ -- Bayer HealthCare was honored by the National Organization for Rare Disorders (NORD) at their annual "Portraits of Courage" Celebration in Washington, DC on May 8. The event recognized several individuals, foundations and innovator companies that have made substantial contributions to improving the lives of people affected by rare disorders. NORD's celebration of progress is an annual event open to everyone with an interest in rare...

2014-04-23 20:23:23

WHIPPANY, N.J. and THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., April 23, 2014 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals, Inc., an Amgen subsidiary (Nasdaq: AMGN), today announced that The Lancet published online results from the Phase 3 DECISION trial which demonstrated that NEXAVAR(®) (sorafenib) tablets significantly extended the time patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma that is...

2014-04-18 23:02:54

Parker Waichman LLP has filed a lawsuit on behalf of a California woman who alleges that her Mirena IUD perforated her uterus, forcing her to undergo surgery to remove the contraceptive device. The lawsuit alleges that Bayer was negligent with regards to Mirena, and points out that the label does not warn about the risk of spontaneous migration or perforation. New York, NY (PRWEB) April 18, 2014 Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured...

2014-04-02 04:21:20

WHIPPANY, N.J., April 2, 2014 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. today announced that the company has begun to enroll patients in a trial studying Xofigo(®) (radium Ra 223 dichloride) injection in combination with abiraterone acetate and prednisone/prednisolone for the treatment of asymptomatic or mildly symptomatic chemotherapy-naive patients with bone predominant metastatic castration-resistant prostate cancer (mCRPC). The randomized, double-blind, placebo-controlled...

2014-03-11 04:21:19

WHIPPANY, N.J., THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., March 11, 2014 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals, Inc., an Amgen subsidiary (Nasdaq: AMGN), today announced that a Phase 3 trial evaluating the investigational use of NEXAVAR(®) (sorafenib) tablets as an adjuvant treatment for patients with hepatocellular carcinoma (HCC), or liver cancer, who had no detectable disease after surgical resection or local ablation, did not...


Word of the Day
snash
  • To talk saucily.
  • Insolent, opprobrious language; impertinent abuse.
This word is Scots in origin and probably imitative.